



PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 04-183 (400.147))

IN THE APPLICATION OF:

Richards et al.

Serial No. 10/798,090

Filed: March 11, 2004

Title RNA Interference Mediated
Inhibition of Muscarinic Colnergic
Receptor Gene Expression Using
Short Interfering Nucleic Acid (siNA)

)
)
)
) Examiner: To Be Assigned
)
) Group Art Unit: 1636
)
) Confirmation No.: 6030
)
)

TRANSMITTAL LETTER

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir or Madam:

In regard to the above identified application:

1. We are transmitting herewith the attached:

- a. Response and Amendment to Notice to File Missing Parts of Non Provisional Application;
- b. Copy of Notice to File Missing Parts of Non Provisional Application;
- c. Executed combined Declaration and Power of Attorney Document
- d. Statement Under 37 CF.R. 1.,821(f)
- e. Transmittal letters for Copy 1 and Copy 2 of the Sequence Listing on Cd-Rom
- f. 3 Cd-Roms
- g. Return Receipt Postcard.

2. With respect to additional fees,


☒ Attached is a check in the amount of \$65.00 in pursuant to 37 CFR 1.16(e)

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No.13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on September 20, 2004.

Date: September 20, 2004

By :


Christopher P. Singer
Reg. No. 48,701



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No.: 04-183 (400.147))

In the Application of:

Richards, et al.

Art Group: 1636

Serial No.: 10/798,090

Examiner: Not assigned yet

Filed: March 11, 2004

For: RNA Interference Mediated Inhibition of
Muscarinic Cholinergic Receptor Gene
Expression Using Short Interfering
Nucleic Acid (siNA)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

1. The Compact Disc contained herein ("400.147 Sequence Listing") submitted under 37 C.F.R. § 1.52(e):

- ☒ Is formatted for IBM-PC Machines
- ☒ Is compatible with MS-Windows Operating System
- ☒ Contains the file "400.147 Sequence Listing" which is 125,464 bytes in size and was created on 09.20.04.


2. Statement under 37 C.F.R. § 1.52(e)(4): The undersigned certifies that the original CD-R submitted herein, titled "400.147 Sequence Listing" (COPY 2) and the copy CD-R entitled "400.147 Sequence Listing" (COPY 1) are identical in content as required by C.F.R. § 1.52(e)(4).

Respectfully submitted,


McDonnell Boehnen Hulbert & Berghoff LLP

Dated: September 20, 2004

By:


Christopher P. Singer
Reg. No. 48,701

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
32nd Floor
Chicago, Illinois 60606
Phone: 312-913-0001
Fax: 312-913-0002



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/798,090	03/11/2004	Ivan Richards	04-183 (400.147)

020306
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606

CONFIRMATION NO. 6030

FORMALITIES LETTER



OC000000013280340

Date Mailed: 07/20/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

09/23/2004 MMEKONEN 00000084 10798090

FILED UNDER 37 CFR 1.53(b)

01 FC:2051

65.00 OP

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact: